Literature DB >> 21940109

ETS-1 proto-oncogene as a key newcomer molecule to predict invasiveness in laryngeal carcinoma.

Aylin Orgen Calli1, Aysegul Sari, Fulya Cakalagaoglu, Aysegul Aksoy Altinboga, Semih Oncel.   

Abstract

ETS-1 protein is one of the key regulators in tumor invasion and progression. We aimed to evaluate the role of ETS-1 in the invasiveness and progression of laryngeal squamous carcinoma, as well as to determine the correlations between clinicopathological characteristics and expression of this molecule. We assessed the levels of ETS-1 in a total of 96 laryngeal specimens of varying degrees of dysplasia, microinvasive squamous carcinoma (8), and invasive squamous carcinoma (60), using normal mucosal epithelium (10) as a positive control. The relationship between ETS-1 expression and clinicopathological parameters of laryngeal carcinoma was also analyzed. We found a significantly higher ETS-1 expression in invasive laryngeal squamous cell carcinomas than in dysplasia (P<0.001). A correlation between ETS-1 expression scores and grade was detected - T factor, stage, cartilage invasion, lymph node metastasis, as well as depth of invasion in laryngeal tumors. Our study is the first to demonstrate that ETS-1 expression is significantly increased in invasive carcinoma, but it is absent in low-moderate grade laryngeal dysplasia and non-neoplastic laryngeal mucosa. This data suggest that ETS-1 expression may play an important role in tumor invasion, and may function in the initiation of the invasive process in laryngeal squamous cell carcinoma. Copyright Â
© 2011 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940109     DOI: 10.1016/j.prp.2011.07.010

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  8 in total

Review 1.  Review of Ets1 structure, function, and roles in immunity.

Authors:  Lee Ann Garrett-Sinha
Journal:  Cell Mol Life Sci       Date:  2013-01-05       Impact factor: 9.261

2.  MiR-324-5p Suppresses Hepatocellular Carcinoma Cell Invasion by Counteracting ECM Degradation through Post-Transcriptionally Downregulating ETS1 and SP1.

Authors:  Liangqi Cao; Binhui Xie; Xuewei Yang; Huihong Liang; Xiaofeng Jiang; Dawei Zhang; Ping Xue; De Chen; Zili Shao
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

3.  Molecular dissection of the oncogenic role of ETS1 in the mesenchymal subtypes of head and neck squamous cell carcinoma.

Authors:  Christian Gluck; Alexandra Glathar; Maria Tsompana; Norma Nowak; Lee Ann Garrett-Sinha; Michael J Buck; Satrajit Sinha
Journal:  PLoS Genet       Date:  2019-07-15       Impact factor: 5.917

4.  Inhibition of IKKβ/NF-κB signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma.

Authors:  Zejia Yang; Jipei Liao; Kevin J Cullen; Hancai Dan
Journal:  Cell Death Discov       Date:  2020-05-15

5.  Nicotine promotes cervical metastasis of oral cancer by regulating peroxiredoxin 1 and epithelial-mesenchymal transition in mice.

Authors:  Min Wang; Wenwen Niu; Moci Qi; Hui Chen; Min Zhang; Chunxiao Wang; Lihua Ge; Jing Yang; Congcong Miao; Ni Shi; Tong Chen; Xiaofei Tang
Journal:  Onco Targets Ther       Date:  2019-05-01       Impact factor: 4.147

6.  The auto-inhibition mechanism of transcription factor Ets-1 induced by phosphorylation on the intrinsically disordered region.

Authors:  Shangbo Ning; Hong-Jun Chao; Shuangli Li; Rui Zhou; Lei Zou; Xu Zhang; Jun Liu; Dazhong Yan; Mojie Duan
Journal:  Comput Struct Biotechnol J       Date:  2022-02-28       Impact factor: 7.271

7.  miR-144-3p, a tumor suppressive microRNA targeting ETS-1 in laryngeal squamous cell carcinoma.

Authors:  Si-Yi Zhang; Zhong-Ming Lu; Ye-Feng Lin; Liang-Si Chen; Xiao-Ning Luo; Xin-Han Song; Shao-Hua Chen; Yi-Long Wu
Journal:  Oncotarget       Date:  2016-03-08

8.  MicroRNA-769-5p Inhibits Pancreatic Ductal Adenocarcinoma Progression by Directly Targeting and Downregulating ETS Proto-Oncogene 1.

Authors:  Kai Cheng; Lan Feng; Shuang Yu; Changhong Yu; Nannan Chi
Journal:  Onco Targets Ther       Date:  2019-12-31       Impact factor: 4.147

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.